PET for Drug Development and Evaluation:
Can drug development and evaluation be improved by the use of positron emission tomography (PET)? PET is now well established and many PET centres participate in networks that warrant the quality of their research. PET allows one to follow the effect of a drug on a variety of patients' metaboli...
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Dordrecht
Springer Netherlands
1995
|
| Schriftenreihe: | Developments in Nuclear Medicine
26 |
| Schlagworte: | |
| Online-Zugang: | UBR01 URL des Erstveröffentlichers |
| Zusammenfassung: | Can drug development and evaluation be improved by the use of positron emission tomography (PET)? PET is now well established and many PET centres participate in networks that warrant the quality of their research. PET allows one to follow the effect of a drug on a variety of patients' metabolic parameters. In addition, PET may be used to follow the fate in vivo of a compound, allowing visualisation of its binding to specific receptors and a direct study of the mechanism of drug action in normal and pathological situations. The book shows the fields in which PET offers new and unique information for the development of drugs (conception, toxicity, pharmacokinetics and metabolism, clinical research, and relations between clinical and biological effects) and evaluates fields in which PET may shorten the development time of drugs. Audience: Professionals in the pharmaceutical industry in all areas of drug discovery and pharmacology, pre-clinical testing, pharmacokinetics and metabolism, clinical evaluation, registration and regulatory affairs. Government health authority representatives who assess data and documentation on new drug development and radiopharmaceuticals. Academic experts concerned with any of these areas |
| Beschreibung: | 1 Online-Ressource (VIII, 360 p) |
| ISBN: | 9789401104296 |
| DOI: | 10.1007/978-94-011-0429-6 |
Internformat
MARC
| LEADER | 00000nmm a2200000zcb4500 | ||
|---|---|---|---|
| 001 | BV046144721 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190905s1995 |||| o||u| ||||||eng d | ||
| 020 | |a 9789401104296 |9 978-94-011-0429-6 | ||
| 024 | 7 | |a 10.1007/978-94-011-0429-6 |2 doi | |
| 035 | |a (ZDB-2-SME)978-94-011-0429-6 | ||
| 035 | |a (OCoLC)1119013403 | ||
| 035 | |a (DE-599)BVBBV046144721 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 616.0757 |2 23 | |
| 084 | |a XI 1600 |0 (DE-625)152976:12905 |2 rvk | ||
| 245 | 1 | 0 | |a PET for Drug Development and Evaluation |c edited by D. Comar |
| 264 | 1 | |a Dordrecht |b Springer Netherlands |c 1995 | |
| 300 | |a 1 Online-Ressource (VIII, 360 p) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Developments in Nuclear Medicine |v 26 | |
| 520 | |a Can drug development and evaluation be improved by the use of positron emission tomography (PET)? PET is now well established and many PET centres participate in networks that warrant the quality of their research. PET allows one to follow the effect of a drug on a variety of patients' metabolic parameters. In addition, PET may be used to follow the fate in vivo of a compound, allowing visualisation of its binding to specific receptors and a direct study of the mechanism of drug action in normal and pathological situations. The book shows the fields in which PET offers new and unique information for the development of drugs (conception, toxicity, pharmacokinetics and metabolism, clinical research, and relations between clinical and biological effects) and evaluates fields in which PET may shorten the development time of drugs. Audience: Professionals in the pharmaceutical industry in all areas of drug discovery and pharmacology, pre-clinical testing, pharmacokinetics and metabolism, clinical evaluation, registration and regulatory affairs. Government health authority representatives who assess data and documentation on new drug development and radiopharmaceuticals. Academic experts concerned with any of these areas | ||
| 650 | 4 | |a Imaging / Radiology | |
| 650 | 4 | |a Nuclear Medicine | |
| 650 | 4 | |a Pharmacology/Toxicology | |
| 650 | 4 | |a Radiology, Medical | |
| 650 | 4 | |a Nuclear medicine | |
| 650 | 4 | |a Toxicology | |
| 650 | 0 | 7 | |a Positronen-Emissions-Tomografie |0 (DE-588)4129799-4 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittelprüfung |0 (DE-588)4128030-1 |2 gnd |9 rswk-swf |
| 655 | 7 | |8 1\p |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Arzneimittelprüfung |0 (DE-588)4128030-1 |D s |
| 689 | 0 | 1 | |a Positronen-Emissions-Tomografie |0 (DE-588)4129799-4 |D s |
| 689 | 0 | |8 2\p |5 DE-604 | |
| 700 | 1 | |a Comar, D. |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9780792337164 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9789401041911 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9789401104302 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-94-011-0429-6 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SME | ||
| 940 | 1 | |q ZDB-2-SME_1990/2004 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-031524906 | ||
| 883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 883 | 1 | |8 2\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 966 | e | |u https://doi.org/10.1007/978-94-011-0429-6 |l UBR01 |p ZDB-2-SME |q ZDB-2-SME_1990/2004 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804180480475529216 |
|---|---|
| any_adam_object | |
| author2 | Comar, D. |
| author2_role | edt |
| author2_variant | d c dc |
| author_facet | Comar, D. |
| building | Verbundindex |
| bvnumber | BV046144721 |
| classification_rvk | XI 1600 |
| collection | ZDB-2-SME |
| ctrlnum | (ZDB-2-SME)978-94-011-0429-6 (OCoLC)1119013403 (DE-599)BVBBV046144721 |
| dewey-full | 616.0757 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.0757 |
| dewey-search | 616.0757 |
| dewey-sort | 3616.0757 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1007/978-94-011-0429-6 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03441nmm a2200577zcb4500</leader><controlfield tag="001">BV046144721</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190905s1995 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9789401104296</subfield><subfield code="9">978-94-011-0429-6</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-94-011-0429-6</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-94-011-0429-6</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1119013403</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046144721</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.0757</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 1600</subfield><subfield code="0">(DE-625)152976:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">PET for Drug Development and Evaluation</subfield><subfield code="c">edited by D. Comar</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Dordrecht</subfield><subfield code="b">Springer Netherlands</subfield><subfield code="c">1995</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (VIII, 360 p)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Developments in Nuclear Medicine</subfield><subfield code="v">26</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Can drug development and evaluation be improved by the use of positron emission tomography (PET)? PET is now well established and many PET centres participate in networks that warrant the quality of their research. PET allows one to follow the effect of a drug on a variety of patients' metabolic parameters. In addition, PET may be used to follow the fate in vivo of a compound, allowing visualisation of its binding to specific receptors and a direct study of the mechanism of drug action in normal and pathological situations. The book shows the fields in which PET offers new and unique information for the development of drugs (conception, toxicity, pharmacokinetics and metabolism, clinical research, and relations between clinical and biological effects) and evaluates fields in which PET may shorten the development time of drugs. Audience: Professionals in the pharmaceutical industry in all areas of drug discovery and pharmacology, pre-clinical testing, pharmacokinetics and metabolism, clinical evaluation, registration and regulatory affairs. Government health authority representatives who assess data and documentation on new drug development and radiopharmaceuticals. Academic experts concerned with any of these areas</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Imaging / Radiology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nuclear Medicine</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacology/Toxicology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Radiology, Medical</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nuclear medicine</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Toxicology</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Positronen-Emissions-Tomografie</subfield><subfield code="0">(DE-588)4129799-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelprüfung</subfield><subfield code="0">(DE-588)4128030-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="8">1\p</subfield><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Arzneimittelprüfung</subfield><subfield code="0">(DE-588)4128030-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Positronen-Emissions-Tomografie</subfield><subfield code="0">(DE-588)4129799-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="8">2\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Comar, D.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9780792337164</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9789401041911</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9789401104302</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-94-011-0429-6</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_1990/2004</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031524906</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">2\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-94-011-0429-6</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_1990/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| genre | 1\p (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV046144721 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T08:36:26Z |
| institution | BVB |
| isbn | 9789401104296 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031524906 |
| oclc_num | 1119013403 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (VIII, 360 p) |
| psigel | ZDB-2-SME ZDB-2-SME_1990/2004 ZDB-2-SME ZDB-2-SME_1990/2004 |
| publishDate | 1995 |
| publishDateSearch | 1995 |
| publishDateSort | 1995 |
| publisher | Springer Netherlands |
| record_format | marc |
| series2 | Developments in Nuclear Medicine |
| spelling | PET for Drug Development and Evaluation edited by D. Comar Dordrecht Springer Netherlands 1995 1 Online-Ressource (VIII, 360 p) txt rdacontent c rdamedia cr rdacarrier Developments in Nuclear Medicine 26 Can drug development and evaluation be improved by the use of positron emission tomography (PET)? PET is now well established and many PET centres participate in networks that warrant the quality of their research. PET allows one to follow the effect of a drug on a variety of patients' metabolic parameters. In addition, PET may be used to follow the fate in vivo of a compound, allowing visualisation of its binding to specific receptors and a direct study of the mechanism of drug action in normal and pathological situations. The book shows the fields in which PET offers new and unique information for the development of drugs (conception, toxicity, pharmacokinetics and metabolism, clinical research, and relations between clinical and biological effects) and evaluates fields in which PET may shorten the development time of drugs. Audience: Professionals in the pharmaceutical industry in all areas of drug discovery and pharmacology, pre-clinical testing, pharmacokinetics and metabolism, clinical evaluation, registration and regulatory affairs. Government health authority representatives who assess data and documentation on new drug development and radiopharmaceuticals. Academic experts concerned with any of these areas Imaging / Radiology Nuclear Medicine Pharmacology/Toxicology Radiology, Medical Nuclear medicine Toxicology Positronen-Emissions-Tomografie (DE-588)4129799-4 gnd rswk-swf Arzneimittelprüfung (DE-588)4128030-1 gnd rswk-swf 1\p (DE-588)4143413-4 Aufsatzsammlung gnd-content Arzneimittelprüfung (DE-588)4128030-1 s Positronen-Emissions-Tomografie (DE-588)4129799-4 s 2\p DE-604 Comar, D. edt Erscheint auch als Druck-Ausgabe 9780792337164 Erscheint auch als Druck-Ausgabe 9789401041911 Erscheint auch als Druck-Ausgabe 9789401104302 https://doi.org/10.1007/978-94-011-0429-6 Verlag URL des Erstveröffentlichers Volltext 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk 2\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
| spellingShingle | PET for Drug Development and Evaluation Imaging / Radiology Nuclear Medicine Pharmacology/Toxicology Radiology, Medical Nuclear medicine Toxicology Positronen-Emissions-Tomografie (DE-588)4129799-4 gnd Arzneimittelprüfung (DE-588)4128030-1 gnd |
| subject_GND | (DE-588)4129799-4 (DE-588)4128030-1 (DE-588)4143413-4 |
| title | PET for Drug Development and Evaluation |
| title_auth | PET for Drug Development and Evaluation |
| title_exact_search | PET for Drug Development and Evaluation |
| title_full | PET for Drug Development and Evaluation edited by D. Comar |
| title_fullStr | PET for Drug Development and Evaluation edited by D. Comar |
| title_full_unstemmed | PET for Drug Development and Evaluation edited by D. Comar |
| title_short | PET for Drug Development and Evaluation |
| title_sort | pet for drug development and evaluation |
| topic | Imaging / Radiology Nuclear Medicine Pharmacology/Toxicology Radiology, Medical Nuclear medicine Toxicology Positronen-Emissions-Tomografie (DE-588)4129799-4 gnd Arzneimittelprüfung (DE-588)4128030-1 gnd |
| topic_facet | Imaging / Radiology Nuclear Medicine Pharmacology/Toxicology Radiology, Medical Nuclear medicine Toxicology Positronen-Emissions-Tomografie Arzneimittelprüfung Aufsatzsammlung |
| url | https://doi.org/10.1007/978-94-011-0429-6 |
| work_keys_str_mv | AT comard petfordrugdevelopmentandevaluation |